Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China
Xiang Xiao, Shuming Ji, Tao Zheng, Tianzhu Wang, Dapeng Jiang, Fang Liu · 2024
Read Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China by Xiang Xiao, Shuming Ji, Tao Zheng, Tianzhu Wang, Dapeng Jiang, Fang Liu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11649429.txt.
Description
Xiang Xiao and co-authors compare kidney outcomes for a newer class of diabetes drug in real Chinese hospital records, in a 2024 paper. The drugs, called SGLT2 inhibitors, lower blood sugar by letting it spill into urine. Trials abroad suggest they also protect the kidneys, but day-to-day evidence from mainland China was scarce. The team studied patients who had both type 2 diabetes and chronic kidney disease.
Records from West China Hospital covered 944 such patients. Of them, 605 started the newer drugs, and 339 took older glucose-lowering medicines. Follow-up ran for a median of about seventeen to twenty-one months. The newer-drug group lost kidney function more slowly, with the yearly slide in their filtration rate clearly smaller. The study adds real-world weight to using these drugs when diabetes and kidney disease arrive together.
Catalog record
| CREATOR | Xiang Xiao, Shuming Ji, Tao Zheng, Tianzhu Wang, Dapeng Jiang, Fang Liu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |